Next 10 |
2024-05-13 08:19:44 ET More on pre-market losers & stocks. AEye, Inc. (LIDR) Q4 2023 Earnings Call Transcript World’s first pig-to-human kidney transplant performed in U.S Seeking Alpha’s Quant Rating on Eledon Pharmaceuticals Historical ear...
2024-05-09 13:54:59 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eledon Pharma (NASDAQ: ELDN ) just reported results for the first quarter of 2024. Eledon Pharma reported earnings per share of -34 cents. This was above the analyst estim...
2024-05-09 08:04:16 ET More on Eledon Pharmaceuticals World’s first pig-to-human kidney transplant performed in U.S Seeking Alpha’s Quant Rating on Eledon Pharmaceuticals Historical earnings data for Eledon Pharmaceuticals Financial information ...
Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Reported updated data from ongoing Phas...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will present a p...
2024-05-07 12:15:04 ET H.C. Wainwright analyst issues BUY recommendation for ELDN on May 7, 2024 10:19AM ET. The previous analyst recommendation was Buy. ELDN was trading at $2.2001 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 1...
2024-05-07 08:31:00 ET More on pre-market losers & stocks. Bilibili Stock Downgraded To Sell After Assessing Q4 Earnings Bilibili Inc. (BILI) Q4 2023 Earnings Call Transcript Bilibili Inc. 2023 Q4 - Results - Earnings Call Presentation Bilibili reiterated...
First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of reje...
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has entered into a securities purchase agreement with certain institutional and accredited healthcare investors for a private investment in public equity f...
News, Short Squeeze, Breakout and More Instantly...
Eledon Pharmaceuticals Inc Com Company Name:
ELDN Stock Symbol:
NASDAQ Market:
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will pa...
Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Reported updated data from ongoing Phas...